Vertex Pharmaceuticals Clinical Trial Pipeline — 29 Active Studies

Vertex Pharmaceuticals pipeline at a glance (March 2026)

About the Vertex Pharmaceuticals clinical program

Vertex Pharmaceuticals has achieved a near-monopoly in cystic fibrosis (CF) through its CFTR modulator franchise. Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) is the standard of care for approximately 90% of CF patients with at least one F508del mutation, generating over $9 billion in annual revenue. Vertex is now pursuing the remaining ~10% of CF patients with the next-generation triple combination VX-522, designed for patients whose mutations do not respond to current modulators. Beyond CF, Vertex is executing a bold expansion into adjacent rare diseases: VX-880 and CTX001/exa-cel (partnered with CRISPR Therapeutics) for sickle cell disease and beta-thalassemia, VX-147 (inaxaplin) targeting APOL1-mediated kidney disease — a condition affecting Black patients disproportionately — and suzetrigine (VX-548) for acute and neuropathic pain via selective NaV1.8 sodium channel blockade, which received FDA approval as the first new non-opioid pain mechanism in decades.

Key therapeutic areas

• Cystic fibrosis (CFTR modulators)
• Sickle cell disease / beta-thalassemia (gene editing)
• APOL1-mediated kidney disease (VX-147)
• Non-opioid pain (NaV1.8 inhibition)
• Alpha-1 antitrypsin deficiency (AATD)
• Type 1 diabetes (islet cell therapy)

Key pipeline programs

• Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) — CF CFTR modulator
• VX-522 — next-gen CFTR triple combo for non-F508del patients
• Exa-cel (exagamglogene autotemcel) — CRISPR gene editing, SCD/beta-thalassemia
• VX-147 (inaxaplin) — APOL1 inhibitor, kidney disease
• Suzetrigine (VX-548) — NaV1.8 inhibitor, acute/neuropathic pain
• VX-880 — allogeneic islet cell therapy, Type 1 diabetes

Top Vertex Pharmaceuticals trial indications

Condition / Indication	Trials
["Cystic Fibrosis"]	9
["Diabetic Peripheral Neuropathic Pain"]	4
["Autosomal Dominant Polycystic Kidney Disease (ADPKD)"]	4
["Myotonic Dystrophy Type 1 (DM1)"]	2
["Type 1 Diabetes", "Kidney Transplant"]	1
["Proteinuric Kidney Disease"]	1
["Sickle Cell Disease"]	1
["Pain"]	1

Why monitor Vertex Pharmaceuticals's clinical trial activity

Vertex's expansion beyond CF is the most-watched rare disease story in pharma. VX-147 could be the first APOL1-targeted therapy — a massive unmet need in a genetically defined population. Their islet cell therapy program (VX-880) is the leading signal for a functional T1D cure. Monitoring Vertex's trial registrations reveals expansion into ADPKD, AATD, and new pain indications.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Vertex Pharmaceuticals's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Vertex Pharmaceuticals trials

• Sponsor normalization: Vertex Pharmaceuticals may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What diseases does Vertex Pharmaceuticals focus on in clinical trials?

Vertex's primary focus remains cystic fibrosis — with next-generation CFTR modulators targeting patients not yet served by Trikafta. Beyond CF, active programs target APOL1-mediated kidney disease (VX-147), sickle cell disease and beta-thalassemia (exa-cel, gene editing with CRISPR Therapeutics), Type 1 diabetes (VX-880 islet cell therapy), autosomal dominant polycystic kidney disease (ADPKD), alpha-1 antitrypsin deficiency (AATD), and neuropathic pain (NaV1.8 inhibition).

How many Vertex trials are currently recruiting?

Based on current ClinicalTrials.gov data, 14 Vertex-sponsored trials are actively recruiting patients. Vertex's trial count is smaller than large-cap pharma because they run highly focused, well-funded programs rather than broad spray-and-pray portfolios.

Can DataLookout alert me to new Vertex rare disease trial registrations?

Yes. DataLookout monitors ClinicalTrials.gov daily for Vertex trial updates. Create a watchlist for Vertex to receive alerts when new trials are registered, when status changes from active-not-recruiting to recruiting, or when enrollment expands. This is particularly valuable for the VX-147 and gene therapy programs where site additions signal geographic expansion.